- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Childhood Sexual Abuse Litigation
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Restructuring and Business Bankruptcy
- Wealth Planning, Administration, and Disputes
- Litigation Support Services
-
January 21, 2020Human Rights Campaign Names Robins Kaplan LLP a “Best Place to Work for LGBTQ Equality” for the Twelfth Consecutive Year
-
January 17, 2020Patrick Arenz Named to America's Top 100 List for High-Stakes Litigation
-
January 08, 2020Bremer Bank Employee-Shareholders File Class Action Lawsuit Against Three Trustees of Otto Bremer Trust
-
January 24, 2020Elimination of Bias: Seeing Juveniles with Justice
-
January 28, 2020Boston 1L Diversity Summer Associate Program Reception
-
January 29-30, 2020American Bar Association Tort Trial & Insurance Practice Section Fidelity & Surety Law Midwinter Conference
-
January 10, 2020Top Tips for Trying Your First (or Next) Patent Jury Trial
-
January 2020A Victory for All Involved
-
January 2020Facing the Music: Protecting Photography in the Age of Instagram
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Investment Decisions for Investors and Entrepreneurs Considering 505(b)(2) Drug Applications
How to Make Sure Your Train Is on the Fast Track
April 19, 2017
Webinar
Related Professionals
Jake M. Holdreith
Partner
Are you an investor or entrepreneur considering 505(b)(2) drug applications? Join Jake Holdreith, Robins Kaplan, and Ken Phelps, Camargo Pharmaceutical Services for a complimentary webinar. Jake and Ken will discuss in detail the topics listed below:
- Does your new drug application support your legal strategy?
- When is it likely that the FDA will treat product as a drug/device combination?
- What do the FDA’s pre-submission comments really mean for your application?
- How can you predict when the FDA will ask to identify the reference listed drug in a literature based 505(b)(2) filing?
This complimentary webinar will be followed with a Q & A session.
Related Publications
September 26, 2018
February 10, 2015
July 15, 2013
Aventis Pharma., Inc. v. Amino Chemicals Ltd.
GENERICally Speaking Summer 2013
Related News
March 21, 2011
January 25, 2008
Mylan Hit With $69.2M In Treble Damages
Competition Law360
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.